Columbia Initiative in Cell Engineering and Therapy
Columbia Initiative in Cell Engineering and Therapy
Cell-based therapies hold great promise for the future of medicine. From cancer and inherited disorders to autoimmune and degenerative diseases, engineered cells utilized as living drugs, including CAR T therapy, offer unprecedented therapeutic potential to alleviate or cure conditions once considered untreatable.
The Columbia Initiative in Cell Engineering and Therapy (CICET) is a university-wide academic endeavor to advance transformative cell and gene therapies. Harnessing Columbia’s collective excellence across the Vagelos College of Physicians and Surgeons, the School of Engineering and Applied Sciences, the Faculty of Arts and Sciences, and in partnership with NewYork-Presbyterian Hospital, CICET unites discovery science with clinical translation.
News and Announcements
- May 22, 2025
Columbia cell therapy pioneer Michel Sadelain has received the 2025 Merkin Prize in Biomedical Technology.
-
Dr. Maksim Mamonkin, Associate Professor of Pediatrics at Columbia and CICET, advances CAR T-cell therapies for T-cell malignancies and leads translational research in pediatric oncology.
